Background
Methods
Subjects
Measurements
Analysis
Results
Characteristics | N | (%) |
---|---|---|
Age, yrs, mean (SD) | 56.1 | (9.6) |
Female | 406 | (88.3) |
Education completed | ||
Junior high school | 114 | (24.8) |
High school | 251 | (54.6) |
Junior college or higher | 95 | (20.6) |
Disease duration, yrs, mean (SD) | 11.4 | (9.5) |
ACR class | ||
1 | 76 | (16.5) |
2 | 322 | (70.0) |
3 | 62 | (13.5) |
Joint stage* | ||
1 | 55 | (12.0) |
2 | 98 | (21.3) |
3 | 113 | (24.6) |
4 | 194 | (42.2) |
Afflicted joint* count (0–49), mean (SD) | 10.0 | (8.8) |
No. of extra-articular complications* | ||
0 | 351 | (76.3) |
1 | 83 | (18.0) |
2+ | 26 | (5.7) |
C-reactive protein, mg/dl, mean (SD) | 1.63 | (2.11) |
Medical treatments† | ||
Methotrexate use | 194 | (42.2) |
Corticosteroids use | 205 | (44.6) |
Other DMARDs use | 246 | (53.5) |
Characteristics | Antiemotionality (RCF score*) | P† | ||
---|---|---|---|---|
Low N = 145 | Moderate N = 157 | High N = 158 | ||
Female | 82.8 | 86.6 | 95.0 | .001 |
Age, yrs, mean (SD) | 54.9 (10.0) | 56.0 (10.3) | 57.4 (8.5) | .033 |
Education, college or higher | 22.8 | 20.4 | 19.0 | .85 |
Duration, yrs, mean (SD) | 11.6 (9.8) | 9.9 (8.5) | 12.7 (10.0) | .41 |
ACR class > = 3 | 13.8 | 11.5 | 15.2 | .75 |
Joint stage‡ > = 3 | 65.5 | 66.2 | 68.4 | .45 |
Afflicted joints‡ count, mean (SD) | 9.9 (9.4) | 9.0 (7.8) | 11.1 (9.0) | .028 |
No. extra-articular complications‡ > = 1 | 23.5 | 23.0 | 24.7 | .49 |
CRP, mg/dl, mean (SD) | 1.49 (1.87) | 1.76 (2.50) | 1.63 (1.90) | .12 |
Methotrexate use | 38.6 | 43.4 | 44.3 | .48 |
Corticosteroids use | 44.8 | 42.0 | 46.8 | .86 |
Other DMARDs use | 54.5 | 54.1 | 51.9 | .95 |
Baseline variables | Model 1 | Model 2 | ||||
---|---|---|---|---|---|---|
OR | (95% CI) | P | OR | (95% CI) | P | |
Antiemotionality (RCF score*) | 1.40 | (1.05-1.87) | .023 | 1.47 | (1.07-2.00) | .016 |
ACR class | 10.52 | (5.87-18.9) | <.001 | 6.13 | (3.17-11.8) | <.001 |
Female sex | 1.92 | (0.53-6.98) | .32 | |||
Age | 1.00 | (0.96-1.04) | .99 | |||
Joint stage* | 1.20 | (0.80-1.78) | .38 | |||
Afflicted joints* count | 1.03 | (1.00-1.07) | .06 | |||
No. extra-articular complications* | 1.40 | (0.96-2.02) | .08 | |||
Log. C-reactive protein | 1.30 | (0.99-1.71) | .06 | |||
Methotrexate use | 1.39 | (0.67-2.88) | .38 | |||
Corticosteroids use | 0.43 | (0.20-0.94) | .034 | |||
Other DMARDs use | 1.12 | (0.54-2.32) | .76 | |||
Education level | 0.80 | (0.52-1.23) | .30 |